<SEC-DOCUMENT>0001193125-19-001663.txt : 20190103
<SEC-HEADER>0001193125-19-001663.hdr.sgml : 20190103
<ACCEPTANCE-DATETIME>20190103171636
ACCESSION NUMBER:		0001193125-19-001663
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190101
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190103
DATE AS OF CHANGE:		20190103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330024450
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		19506915

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d679435d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): January&nbsp;1, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-14888</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">33-0969592</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 110 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting, PA 19462 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(267) <FONT STYLE="white-space:nowrap">440-4200</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT
STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2019, Avtar Dhillon provided notice to the Board
of Directors (the &#147;<B><I>Board</I></B>&#148;) of Inovio Pharmaceuticals, Inc. (the &#147;<B><I>Company</I></B>&#148;) of his decision to resign as a member and as Chairman of the Board, effective immediately. Dr.&nbsp;Dhillon&#146;s decision to
resign was not the result of any disagreement with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;3, 2019, the Board appointed Simon X. Benito, a current
director of the Company, as Chairman of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;3, 2019, the Board also appointed Lota S. Zoth to serve as a director
of the Company. Ms.&nbsp;Zoth&#146;s term will continue until the Company&#146;s 2019 Annual Meeting of Stockholders. There is no arrangement or understanding between Ms.&nbsp;Zoth and any other person pursuant to which she was selected as a
director of the Company, and there is no family relationship between Ms.&nbsp;Zoth and any of the Company&#146;s other directors or executive officers. The Company is not aware of any transaction involving Ms.&nbsp;Zoth requiring disclosure under
Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> Additional information regarding Ms.&nbsp;Zoth is set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lota S. Zoth, age 59, commenced service as a director on the Board on January&nbsp;3, 2019. Since 2008, she has served on the board of
directors of several publicly held biopharmaceutical companies and currently serves on the boards of directors of Orexigen Therapeutics, Inc., Circassia Pharmaceuticals, PLC, NewLink Genetics Corporation, Spark Therapeutics, Inc. and Zymeworks Inc.
She also served on the boards of directors of the public companies Hyperion Therapeutics, Inc. from 2008 to May 2015 and Ikaria, Inc. from 2008 to 2014. Prior to her board service, she served in senior financial roles in a variety of
commercial-stage companies, including serving as MedImmune Inc.&#146;s corporate controller from 2002 to 2004 and its chief financial officer from 2004 until its acquisition by AstraZeneca in 2007. Prior to joining MedImmune in 2002, Ms.&nbsp;Zoth
served in financial executive roles at PSINet&nbsp;Inc., Sodexho Marriott Services, Inc., Marriott International and PepsiCo, Inc. Ms.&nbsp;Zoth also served as an auditor at Ernst&nbsp;&amp; Young,&nbsp;LLP and is a Certified Public Accountant.
Ms.&nbsp;Zoth received a B.B.A. in accounting from Texas Tech University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Zoth will be compensated in accordance with the
Company&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy. She will receive an annual cash retainer of $45,000 for serving on the Board. In addition, Ms.&nbsp;Zoth received initial equity awards under and
pursuant to the Company&#146;s 2016 Omnibus Incentive Plan upon her appointment as of January&nbsp;3, 2019, the date of grant. As a newly elected director, Ms.&nbsp;Zoth was awarded 12,270 restricted stock units and a stock option to purchase 20,000
shares of the Company&#146;s common stock at an exercise price of $4.28, the closing price of the Company&#146;s common stock on the date of grant. The restricted stock units will vest over a period of three years, with <FONT
STYLE="white-space:nowrap">one-third</FONT> of the shares vesting on each of the first, second and third anniversaries of the grant date, subject to Ms.&nbsp;Zoth&#146;s continued service as a director of the Company as of each vesting date. With
respect to the shares of common stock underlying the stock option grant, <FONT STYLE="white-space:nowrap">one-quarter</FONT> of the shares vested as of the grant date, with the remainder vesting in three equal annual installments on the first,
second and third anniversaries of the grant date, subject to Ms.&nbsp;Zoth&#146;s continued service as a director of the Company as of each vesting date. Ms.&nbsp;Zoth will be eligible to receive additional annual equity awards on each date of the
Company&#146;s annual meeting of stockholders in accordance with the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulation FD Disclosure. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;3, 2019, the Company issued a press release announcing the resignation of Dr.&nbsp;Dhillon and the appointment of Ms.&nbsp;Zoth
to the Board. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report. The information contained in the press release furnished as Exhibit 99.1 shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18
of the Securities Exchange Act of 1934, as amended (the &#147;<B><I>Exchange Act</I></B>&#148;), and is not incorporated by reference into any of the Company&#146;s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d679435dex991.htm">Press Release dated January&nbsp;3, 2019</A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INOVIO PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: January&nbsp;3, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Peter Kies</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Peter Kies</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d679435dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 99.1 </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g679435inovio.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS: </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investors:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ben Matone, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">484-362-0076,</FONT></FONT> <U>ben.matone@inovio.com</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Media:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jeff Richardson, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">267-440-4211,</FONT></FONT> <U>jrichardson@inovio.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Announces Appointments to its Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Simon X. Benito, Director Since 2003, Named Chairman of the Board; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lota Zoth, former MedImmune CFO, Joins Board </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, PA &#150; January&nbsp;3, 2019 &#150; Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that Mr.&nbsp;Simon&nbsp;X. Benito, former
Merck Vaccines executive, has been appointed Chairman of Inovio&#146;s Board of Directors, replacing Dr.&nbsp;Avtar Dhillon who is retiring from the Board after 10 years of service. Dr.&nbsp;Dhillon was initially appointed as Chairman of the Board
in 2009 in conjunction with the merger between Inovio Biomedical and VGX Pharmaceuticals with a mandate to provide continuity and strategic guidance during its integration. Effective immediately, Mr.&nbsp;Benito will assume the role of Chairman.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the appointment of Mr.&nbsp;Benito, Inovio welcomes Ms.&nbsp;Lota Zoth to the company&#146;s Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;J. Joseph Kim, Inovio&#146;s President and CEO, said, &#147;Our Board has played a critical role in our success and that will continue with Simon
Benito as our Chairman. For more than 15 years, he has brought to our Board many years of business experience in the pharmaceutical industry, formal accounting and financial expertise, significant public company board experience, and important
industry contacts. We also welcome Lota Zoth, an experienced financial executive, who has a <FONT STYLE="white-space:nowrap">35-year</FONT> track record of helping public and private companies to sustainable growth and innovation through financings,
acquisitions, and strategic planning.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Finally, with gratitude we thank Avtar Dhillon, Board Chairman since 2009, for his total of 17 years of
dedicated service to Inovio. Avtar provided strong leadership especially during the integration and <FONT STYLE="white-space:nowrap">build-up</FONT> after the merger of Inovio Biomedical and VGX that led to the formation of Inovio Pharmaceuticals in
2009.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lota Zoth has held senior financial roles in a variety of commercial-stage companies, including serving as MedImmune&#146;s chief financial
officer. Prior to joining MedImmune, Ms.&nbsp;Zoth served in financial executive roles with PSINet Inc., Sodexho Marriott Services, Inc., Marriott International and PepsiCo, Inc. Ms.&nbsp;Zoth was also an auditor at Ernst&nbsp;&amp; Young, LLP and
is a Certified Public Accountant. She has experience of serving on the board of multiple public companies in the biopharmaceutical industry, including Spark Therapeutics currently. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simon Benito, a Director of Inovio since 2003, previously held various leadership positions at Merck&nbsp;&amp; Co. including senior vice president of Merck
Vaccine Division and vice president of Merck Human Health for Japan. Mr.&nbsp;Benito also served as executive vice president of Merck-Medco Managed Care. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is a
late-stage biotechnology company focused on the discovery, development, and commercialization of DNA immunotherapies that transform the treatment of cancer and infectious diseases. Inovio&#146;s proprietary platform technology applies
next-generation antigen sequencing and DNA delivery to activate potent immune responses to targeted diseases. The technology functions exclusively in vivo, and has been demonstrated to consistently activate robust and fully functional T cell and
antibody responses </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
against targeted cancers and pathogens. Inovio is the only immunotherapy company that has reported generating T cells whose killing capacity correlates with relevant clinical outcomes.
Inovio&#146;s most advanced clinical program, <FONT STYLE="white-space:nowrap">VGX-3100,</FONT> is in Phase 3 for the treatment of <FONT STYLE="white-space:nowrap">HPV-related</FONT> cervical <FONT STYLE="white-space:nowrap">pre-cancer.</FONT> Also
in development are Phase 2 immuno-oncology programs targeting head and neck cancer, bladder cancer, and glioblastoma, as well as platform development programs in hepatitis B, Zika, Ebola, MERS, and HIV. Partners and collaborators include MedImmune,
Regeneron, Roche/Genentech, ApolloBio Corporation, The Bill&nbsp;&amp; Melinda Gates Foundation, The Wistar Institute, University of Pennsylvania, Parker Institute for Cancer Immunotherapy, CEPI, DARPA, GeneOne Life Science, Plumbline Life Sciences,
Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit www.inovio.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain
forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs, including the planned
initiation and conduct of clinical trials and the availability and timing of data from those trials. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies, clinical trials and product development programs, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology
as a delivery mechanism or develop viable DNA vaccines, our ability to support our pipeline of SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> active immunotherapy and vaccine products, the ability of our collaborators to attain
development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies
or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product
liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly
infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our
technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for
the year ended December&nbsp;31, 2017, our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2018 and other regulatory filings we make from time to time. There can be no assurance that any
product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the
forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.
</I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g679435inovio.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g679435inovio.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M]Y+I&IRFX=8S)%,WWN",@GOUI >GT % !0 4 % !0 4 % !0 4 % !0 4 %
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M+2-@S)$Q9I,=NG I@>R    # %( H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@#ROXC^,M=\/^(HK33;P0P-;JY4Q*W))'4CVH V_AGXBU/Q%I
MM]-J=P)GBE"H0BK@8]@* .YH \_^)WB;5O#D>FG2[D0&8R;\QJV<;<=0?4T
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M,] _L7PM'-*FVYO<3/GJ%_A'Y<_C2&=G0!QWQ1_Y$&]_WX__ $,4 >1> /\
MD>M)_P"NI_\ 033$?1U(9PWQ7U-K#P>;>-B'O)1$<?W1R?Y ?C0!Y5X$T5-=
M\6VEK,NZW0F64'NJ\X_$X'XTP/HX    8 [4@"@ H Q?%>BQZ]X;O+%U!D*%
MXC_=<<@_T_&@#YPL+R73=2M[N$E9;>0.OU!IB/J2VG2YM8;B/[DJ!U^A&:0S
MQ/XP?\C=!_UZK_Z$U,#I/@Q_R!M3_P"NZ_\ H- 'IM(#RGXU?ZG1_P#>E_\
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MT@/*/!>@GQ#XGM;-ES I\R8_[ Z_GP/QIB/I%5"J%4  #  [4ABT <=\4?\
MD0;W_?C_ /0Q0!Y%X _Y'K2?^NI_]!-,1]'4AGE_QH5O[,TIA]T2N#]<#']:
M ,#X.LB^*[E6^\;1MO\ WTM,#V^D 4 % "$@ D\ 4 ?*EV5:]G9/NF1B/IFF
M(^F?#@9?"^D!OO"SB!^NP4AGD/Q@_P"1N@_Z]5_]":F!TGP8_P"0-J?_ %W7
M_P!!H ]-I >4_&K_ %.C_P"]+_[+0!F_!G_D/:A_U[?^S"F![12 * /'OC1_
MR$=)_P"N3_S%,!_P6_X^]7_W(_YM0!Z]2 ^=_'VE/I7C&^0KB.=_/C/J&Y_G
MD?A7T^#J*=%>6A\MC*;IUI+OJ=5\'M62*[OM)D8!I@)8@>Y'##\L?E7'F=-N
M*FNAVY742DZ;ZGKU>(>X% !0 4 -DW^4_EX#X.W/3--;ZB=[:'S!J-K?PZK/
M#?12"\,AWJP^8L3^M?6PE!Q3CL?(3C-3:EN>U?#+PY-H>@O<7<1CN[Q@Q1A@
MJ@^Z#^9/XUX./KJK4M'9'OY?0=*G>6[.WKSST2.:&.X@D@E4/'(I5E/0@\$4
M ?,WB31I- \07>G/G$3_ ",?XD/*G\J8ANL:Y>:X]JUX^XVT"P)]!W^IH ]=
M^$V@?V?H#ZI,F)[X_+GM&.GYG)_*D,]"H * ..^*/_(@WO\ OQ_^AB@#R+P!
M_P CUI/_ %U/_H)IB/HZD,X[XFZ0VJ^#9WB7=+:,)P!Z#AOT)/X4 >,>$];/
MA[Q+9Z@<F)&VR@=T/!_Q_"F(^E()HKF".>%UDBD4,K*<@@]#2&24 % ',>._
M$,?A_P ,W#AP+JX4Q0+WR1R?P'/Y4 >!Z+ILNL:U::?"#NGD"\=AW/X#)IB/
MJ"*-88DB081%"J/0"D,\1^,'_(W0?]>J_P#H34P.D^#'_(&U/_KNO_H- 'IM
M(#RGXU?ZG1_]Z7_V6@#-^#/_ "'M0_Z]O_9A3 ]HI % 'CWQH_Y".D_]<G_F
M*8#_ (+?\?>K_P"Y'_-J /7J0'*^.?"">*=+'E%4O[?)A<]#ZJ?8UV83$NA+
M79G%B\,L1#3=;'A0&H^'M74E9+2^M7R 1@J1_,?SKZ'W*L.Z9\Y[]&?9H]P\
M)>/M.\10)!.Z6NH@8:)C@.?53W^G6O Q.#G1=UJCZ+#8V%96>DCKZX3N"@!&
M944LS!5')). * V,B/6UU.X:WT?$ZH<2W6,Q1^P/\3>PX]36[I<BO4T\NO\
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M7'ZXI@6K'X1^(KAP+EK:T3N6DW'\E_QH ]$\,?#K2/#CI<L#>7J\B64<(?\
M97M]>32 ["@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
A H * "@ H * "@ H * "@ H * "@ H * "@ H * /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
